Nadofaragene Firadenovec Management in Real-World BCG-Unresponsive Bladder Cancer: A Case-based Discussion – Mark Tyson
Mark Tyson presents a case-based discussion on BCG-unresponsive non-muscle invasive bladder cancer treatment options. He describes a 67-year-old man with recurrent T1 disease after BCG who refused cystectomy despite high-risk features including lymphovascular invasion. Dr. Tyson outlines multiple treatment options including gemcitabine-docetaxel, pembrolizumab, nadofaragene, and nogapendekin,…
